SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:04f53bf7-d971-4c75-aeb1-da7b8f663c12"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:04f53bf7-d971-4c75-aeb1-da7b8f663c12" > A systematic overvi...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005196naa a2200493 4500
001oai:lup.lub.lu.se:04f53bf7-d971-4c75-aeb1-da7b8f663c12
003SwePub
008160401s2008 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/11538352 URI
0247 a https://doi.org/10.1111/j.1600-0609.2008.01049.x2 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a for2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Berntorp, Eriku Lund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups4 aut0 (Swepub:lu)medf-ebe
2451 0a A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
264 1b Wiley,c 2008
520 a Patients with von Willebrand disease (VWD) and haemophilia A (HA) lack, to varying degrees, the von Willebrand factor (VWF) and coagulation factor VIII (FVIII) that are critical for normal haemostasis. These conditions in turn make patients prone to uncontrolled bleeding. Historically, patients with severe forms of VWD or HA were crippled before adulthood and their life expectancy was significantly reduced. Over the past decades, specific coagulation factor replacement therapies including Haemate P, have been developed to help patients achieve and maintain normal haemostasis. Haemate P is a human, plasma-derived VWF/FVIII medicinal product, which was first licensed in Germany in 1981 for the treatment of HA-associated bleeding. It has since then come to be accepted as the gold standard for both the treatment and prophylaxis of bleeding in VWD, especially in cases where desmopressin [1-deamino-8-D-arginine vasopressin (DDAVP)] has been ineffective. Haemate P was the first effectively virus-inactivated (pasteurisation: 60 degrees C for 10 h in aqueous solution) FVIII product, whereby the risk of potentially threatening infective complications of plasma-derived products was reduced. Haemate P was also shown to have a VWF multimer profile remarkably close to that of normal plasma. This bibliographic review presents previously unpublished clinical data of Haemate P, based upon internal clinical study reports of the proprietor, CSL Behring, in addition to data already presented in other publications. The data demonstrate a predictable and well-characterised pharmacokinetic profile, and a proven record of short- and long-term safety, while effectively correcting the haemostatic defects in VWD and HA. Recently available data have also shown Haemate P to be of haemostatic value in exceptional clinical circumstances including surgical interventions. By virtue of its plasma-derived combination of VWF and FVIII, in addition to its high VWF:FVIII content ratio (2.4:1), Haemate P is also associated with successful immune tolerance induction in those patients developing inhibitor antibodies. Although the theoretical risk of thromboembolic complications does exist while receiving Haemate P, as it does with any FVIII replacement therapy, the incidence of such complications has remained notably low. Given the robust data that have accumulated for the use of Haemate P, dosing recommendations are also described in this review; the recommendations are tailored to patient-specific contexts including baseline VWF and FVIII levels in plasma and the type of surgical intervention being undertaken. A wide variety of studies have also provided data on paediatric and geriatric populations, all of which have suggested that Haemate P can be safely and effectively used in a wide variety of clinical circumstances.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653 a Haemate P
653 a Humate-P
653 a von Willebrand disease
653 a von Willebrand factor
653 a haemophilia
653 a factor VIII
7001 a Archey, William4 aut
7001 a Auerswald, Günter4 aut
7001 a Federici, Augusto B4 aut
7001 a Franchini, Massimo4 aut
7001 a Knaub, Sigurd4 aut
7001 a Kreuz, Wolfhart4 aut
7001 a Lethagen, Stefanu Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine4 aut0 (Swepub:lu)medf-sle
7001 a Mannucci, Pier M4 aut
7001 a Pollmann, Hartmut4 aut
7001 a Scharrer, Inge4 aut
7001 a Hoots, Keith4 aut
7102 a Klinisk koagulationsmedicin, Malmöb Forskargrupper vid Lunds universitet4 org
7730 t European Journal of Haematology. Supplementumd : Wileyg 80:s70, s. 3-35q 80:s70<3-35x 0902-4506x 0902-4441x 1600-0609
8564 u http://www.ncbi.nlm.nih.gov/pubmed/18380871?dopt=Abstracty FULLTEXT
8564 u http://dx.doi.org/10.1111/j.1600-0609.2008.01049.xy FULLTEXT
8564 8u https://lup.lub.lu.se/record/1153835
8564 8u https://doi.org/10.1111/j.1600-0609.2008.01049.x

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy